Intranasal Ebola Vaccine 100% Effective in Animal Study

the MPR take:

A newly published report states that an intranasal Ebola vaccine protected monkeys from the virus 100% of the time – even a year after vaccination – but funding sources have dried up for the project and the research may not continue. The team of scientists from the University of Texas at Austin’s College of Pharmacy have been working for seven years to develop the vaccine, which targets cells in the nasal passages and lungs and creates a body-wide immune system response to prevent infection at the mucosas. In the small study, all nine monkeys given the vaccine (that uses a genetically engineered common cold virus containing a tiny portion of Ebola DNA) provided protection 100% of the time, including a year after vaccination. Other Ebola vaccines are also being tested, but this vaccine’s needle-free administration could make it ideal for preventing accidental needle injuries that can facilitate Ebola infection. Lead researcher Maria Croyle also believes that the vaccine could be stable at room temperature without requiring refrigeration. Croyle hopes to seek funding for additional trials from a pharmaceutical company, the federal government, or both.

Nose Spray Ebola Vaccine Protects Monkeys
Intranasal Ebola Vaccine

A needle-free Ebola vaccine protects monkeys 100 percent of the time from the virus, even a year after they've been vaccinated, researchers reported Monday. But now the research is dead in the water without funding, Maria Croyle of the University of Texas at Austin's College of Pharmacy said. Croyle's team had been working on this one for seven years.